Skip to main content
main-content

Rheumatoid arthritis

Comorbidities

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

24-05-2019 | Rheumatoid arthritis | Highlight | News

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

Glucocorticoid use may increase infection risk in RA patients undergoing joint replacement

Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.

21-05-2019 | Rheumatoid arthritis | News

Short-term JAK inhibitor use not linked to increased CV risk

Rheumatoid arthritis patients receiving Janus kinase inhibitors may not be at increased risk for cardiovascular events in the short term, suggests a meta-analysis of randomized controlled trials comparing the active agents with placebo.

20-05-2019 | Rheumatoid arthritis | Highlight | News

Glucocorticoid use may increase infection risk in RA patients undergoing joint replacement

Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.

24-04-2019 | Rheumatoid arthritis | News

HDL cholesterol levels may predict CV risk in tofacitinib-treated RA patients

Increasing levels of high-density lipoprotein cholesterol are associated with a reduction in cardiovascular risk among rheumatoid arthritis patients undergoing treatment with the Janus kinase inhibitor tofacitinib, researchers report.

18-04-2019 | Rheumatoid arthritis | News

Statins may have some benefits in patients with RA

Findings from the TRACE RA trial suggest that atorvastatin has a favorable safety profile and may reduce low-density lipoprotein cholesterol levels in patients with rheumatoid arthritis.

16-04-2019 | Sexual and reproductive health | News

Inflammatory arthritis may impact sexual function

Findings from a systematic review suggest that sexual dysfunction is common among both men and women with inflammatory arthritis, highlighting the importance of including sexual health in the routine management of rheumatic disease.

15-04-2019 | Biomarkers | News

Calprotectin levels separate septic arthritis from other inflammatory arthritides

Levels of calprotectin in the synovial fluid can be used to discriminate patients with septic arthritis from those with pseudogout and rheumatoid arthritis, shows a report published in Rheumatology.

03-04-2019 | Rheumatoid arthritis | News

Abatacept may not provoke respiratory events in RA patients with COPD

Individuals with rheumatoid arthritis (RA) and chronic obstructive pulmonary disease who are treated with abatacept do not have an elevated risk for adverse respiratory events relative to those given other biologics, real-world study results suggest.

Cardiovascular risk associated with conventional, biologic DMARDs characterized

Tocilizumab is associated with a lower risk for major adverse cardiovascular events than tumor necrosis factor inhibitors among patients with rheumatoid arthritis, whereas the use of conventional DMARDs may be linked to an elevated risk, researchers report.

02-04-2019 | Rheumatoid arthritis | Highlight | News

Cardiovascular risk associated with conventional, biologic DMARDs characterized

Tocilizumab is associated with a lower risk for major adverse cardiovascular events than tumor necrosis factor inhibitors among patients with rheumatoid arthritis, whereas the use of conventional DMARDs may be linked to an elevated risk, researchers report.

01-04-2019 | Rheumatoid arthritis | News

Risk factors for dyspnea identified in RA patients

Older age, female sex, and poor functional status are significant predictors of dyspnea on exertion among patients with rheumatoid arthritis, researchers report.

27-03-2019 | Rheumatoid arthritis | News

Biologics may influence durability of yellow fever vaccine response in RA patients

Treatment with biologics in combination with conventional DMARDs is associated with a reduction in the duration of protective immunity induced by the 17DD yellow fever vaccine among patients with rheumatoid arthritis, research suggests.

20-03-2019 | Rheumatoid arthritis | News

RA disease activity linked to cognitive impairment

Rheumatoid arthritis patients with high disease activity are more likely to have cognitive impairment than those with less active disease, researchers report.

11-03-2019 | Rheumatoid arthritis | News

No impact of comorbidities on efficacy, safety profiles of baricitinib in RA patients

Findings from a post-hoc pooled analysis suggest that comorbidity does not influence the efficacy or safety of baricitinib 4 mg once daily in patients with rheumatoid arthritis who have had an inadequate response to conventional DMARDs.

08-03-2019 | Rheumatoid arthritis | News

Consensus guidelines for management of comorbid RA, cancer examined

A systematic review of consensus recommendations for the management of rheumatoid arthritis in patients with cancer shows agreement in some areas, but highlights the need for further research into topics for which discrepancies exist.

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

25-02-2019 | Vaccination | Highlight | News

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

Cardiovascular risk management in arthritis: Why still a bridge too far?

Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.

Image Credits